8-K: Traws Pharma Reports Q2 Results, Advances Antiviral Pipeline

Traws Pharma announced its second quarter 2025 financial results and provided updates on its prioritized antiviral programs for COVID-19 and influenza.

Summary

• Traws Pharma reported a net loss of $0.9 million for Q2 2025, a significant improvement from a $123.1 million net loss in Q2 2024, which included a one-time charge.
• Revenue for Q2 2025 was $2.7 million, primarily from the recognition of deferred revenue due to the termination of a legacy oncology licensing agreement.
• Cash, cash equivalents, and short-term investments stood at $13.1 million as of June 30, 2025, down from $21.3 million at December 31, 2024.
• The company is prioritizing its ratutrelvir program for COVID-19, with a Phase 2 study protocol submitted to HREC for newly diagnosed patients and a proposed study for PAXLOVID-ineligible patients.
• Phase 1 data for ratutrelvir showed sustained plasma drug levels (4x EC90) over 10 days with good safety and no drug-induced metabolism.
• The Tivoxavir Marboxil (TXM) program for bird flu and seasonal flu is focusing on discussions with BARDA for inclusion in drug stockpiling initiatives.
• Initiation of a Phase 2 study for TXM in bird flu-infected subjects has been deferred due to low incidence rates and the FDA's stance on the Animal Rule.
• TXM demonstrated compelling protection against mortality and disease in preclinical models (mice, ferrets, non-human primates) using H5N1 virus.
• Traws is seeking partnerships for its legacy oncology assets, rigosertib and narazaciclib, with rigosertib showing an 80% overall response rate in RDEB SCC in published data.
• Management changes include Jack Stover as Chairman, Iain D. Dukes as Interim CEO, and Charles Parker as Interim CFO.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While the net loss significantly improved due to a non-recurring event, and cash is declining, the company has made clear progress in advancing its key antiviral pipeline assets (ratutrelvir and TXM) with promising preclinical and Phase 1 data. The strategic focus on high-demand areas like COVID and flu, and the pursuit of stockpiling opportunities, are positive. However, the deferral of the bird flu study and the need for future capital raise temper the overall sentiment.

Positives

• Net loss significantly reduced to $0.9 million in Q2 2025 from $123.1 million in Q2 2024, largely due to the absence of a prior year's one-time charge of $117.5 million.
• Revenue increased to $2.7 million in Q2 2025 from $57 thousand in Q2 2024, driven by deferred revenue recognition from a terminated licensing agreement.
• Ratutrelvir (COVID program) Phase 2 study protocol submitted to HREC, with expectations to report results by year-end 2025.
• Ratutrelvir Phase 1 studies demonstrated favorable pharmacokinetics, maintaining plasma drug levels four times above EC90 over a 10-day period with no drug-induced metabolism and no treatment-related adverse events.
• Ratutrelvir shows superior in vitro potency against various COVID strains, including those resistant to existing therapies like PAXLOVID and ensitrelvir.
• Tivoxavir Marboxil (TXM) program is advancing discussions with BARDA for potential inclusion in the U.S. strategic drug stockpiling initiative for influenza, representing a significant commercial opportunity.
• TXM demonstrated compelling protection against mortality and disease in three well-accepted preclinical flu models (mice, ferrets, non-human primates) using H5N1 virus.
• TXM Phase 1 data showed sustained plasma levels above EC90 for approximately three weeks after a single oral dose with good tolerability, supporting single-dose treatment.
• Legacy oncology asset rigosertib showed a compelling 80% overall response rate and 50% complete responses in RDEB SCC in published clinical efficacy data, highlighting its potential in an area of unmet need.

Negatives

• Cash, cash equivalents, and short-term investments decreased to $13.1 million as of June 30, 2025, from $21.3 million at December 31, 2024, indicating cash burn.
• Initiation of the Phase 2 study for Tivoxavir Marboxil (TXM) incorporating bird flu-infected subjects has been deferred due to the current low incidence rate of bird flu in humans and the FDA's reaffirmation that clinical trial data, not the Animal Rule, is the registrational path for bird flu therapeutics.
• The increase in revenue for Q2 2025 is primarily attributable to a one-time recognition of deferred revenue from a terminated licensing agreement, not recurring operational revenue.

Risks

• Substantial risks and uncertainties are involved in forward-looking statements, which could cause actual results to differ materially.
• Uncertainties associated with product candidates, including risks related to clinical development and regulatory approval, such as potential delays in clinical trials.
• Inability to obtain sufficient additional capital to continue advancing product candidates and operating the business.
• Uncertainties in obtaining successful clinical results for product candidates and potential unexpected costs.
• Risks related to the failure to realize any value from product candidates currently being developed.
• Uncertainties in retaining key personnel, including the executive team and directors.
• Risks stemming from changes in the regulatory, economic, and/or political landscape.
• Disruption and volatility in global currency, capital, and credit markets.
• Risks associated with the possible failure to realize certain anticipated benefits of the 2024 merger with Trawsfynydd Therapeutics, Inc.
• The ongoing need for improved therapy to reduce the frequency of clinical rebound and the concomitant risk for Long COVID.
• The extent of the spread and threat of bird flu.

Future Outlook

The company expects to report results of its Phase 2 studies for ratutrelvir by year-end 2025. It will continue discussions with BARDA regarding the inclusion of TXM in the drug stockpiling initiative for influenza and will carefully monitor CDC data for bird flu transmissions to humans. The company's cash position is expected to support planned operations into Q1 2026. Traws is actively seeking development and commercialization partners for its legacy clinical oncology programs.

Management Comments

• "We have reprioritized our clinical trial plans to reflect potential short and medium-term shareholder value."
• "Our expectation is to be able to report the results of these Phase 2 studies by year-end 2025."
• "We believe that this [BARDA discussions for TXM stockpiling] represents the major short-to-medium-term commercial potential for this program."
• "As the end of summer draws near, we are acutely aware that autumn is a time of heightened COVID and influenza awareness and vulnerability for many people across the country, as both viruses continue to mutate and pose critical threats to human health."
• "We believe that Traws' ritonavir-free COVID and once-daily flu candidates each have the potential to overcome the shortcomings of current treatments and become the new standard of care."
• "Ratutrelvir has an emerging profile that could position it for wide adoption, especially in vulnerable individuals, based on its broad activity against a range of resistant strains."
• "We intend to progress the development of ratutrelvir in the coming months, starting with a Phase 2 study planned to begin soon in the Southern Hemisphere. Positive results could provide important proof-of-concept data and represent a valuable inflection point for the program."

Industry Context

The announcement highlights Traws Pharma's strategic shift to focus on developing novel antiviral therapies for respiratory viral diseases, specifically COVID-19 and influenza, which continue to pose significant public health challenges. This aligns with a broader industry trend recognizing the ongoing need for effective antiviral treatments, especially as vaccine effectiveness wanes and new variants emerge. The company's emphasis on ritonavir-free COVID treatments addresses a critical unmet need for patients ineligible for current therapies like PAXLOVID due to drug-drug interactions. The pursuit of government stockpiling initiatives for influenza treatments, particularly for bird flu, positions Traws within the pandemic preparedness sector, a growing area of focus for global health organizations and governments.

Comparison to Industry Standards

• Ratutrelvir is positioned as a potential 'best-in-class' ritonavir-free agent for COVID-19, directly comparing its safety and efficacy against PAXLOVID (Pfizer), which reported $427 million in sales in Q2 2025, a 70% increase year-over-year.
• Ratutrelvir demonstrated superior in vitro suppression of COVID-19 virus growth compared to nirmatrelvir (active agent in PAXLOVID), ensitrelvir, and ibuzatrelvir (Pfizer's emerging candidate), across multiple virus strains.
• Ratutrelvir's proposed 10-day, once-daily dosing regimen aims to overcome shortcomings of current treatments like PAXLOVID's 5-day regimen, which is associated with higher rates of clinical rebound and potential for Long COVID.
• Tivoxavir Marboxil (TXM) is being developed as a single-dose treatment for bird flu and seasonal flu, contrasting with existing treatments like oseltamivir (Tamiflu, Roche) and baloxavir (Xofluza, Genentech/Roche), which the human H5N1 virus (A/Texas/37/2024) has shown resistance to.
• TXM's preclinical data in mice, ferrets, and non-human primates using the H5N1 virus isolated from a dairy worker provides a strong foundation for its potential as a stockpiling candidate, addressing a gap where no currently approved bird flu therapies exist.
• The company's legacy oncology asset, rigosertib, showed an 80% overall response rate and 50% complete responses in RDEB SCC, highlighting its potential in an ultra-rare disease with substantial unmet need and no approved therapies, suggesting a strong clinical profile for partnership compared to the lack of existing solutions.

Management Changes

Stakeholder Impact

• **Shareholders:** The significant reduction in net loss (though due to a prior-year charge) and progress in the antiviral pipeline could be viewed positively, potentially increasing investor confidence. However, the declining cash balance and deferred flu study present ongoing financial and operational risks.
• **Patients:** Advancement of ratutrelvir offers potential for a ritonavir-free COVID treatment, benefiting patients ineligible for PAXLOVID. The development of TXM could provide a crucial single-dose treatment for bird flu and seasonal influenza, addressing unmet medical needs.
• **Employees:** The reprioritization of programs and management changes may impact internal roles and focus, potentially leading to shifts in R&D teams.
• **Regulatory Authorities (FDA, BARDA):** Ongoing discussions with FDA and BARDA are critical for regulatory pathways and potential stockpiling agreements, indicating continued engagement and compliance efforts.
• **Partners (Current & Potential):** The termination of a licensing agreement for oncology assets and the active search for new partnerships for these programs indicate a strategic shift that could lead to new collaborations.

Next Steps

• Initiate dosing in a Phase 2 non-inferiority study for ratutrelvir in Australia in Q3 2025.
• Evaluate ratutrelvir in a single-arm study in PAXLOVID-ineligible patients.
• Report results of ratutrelvir Phase 2 studies by year-end 2025.
• Advance discussions with BARDA and other regulatory agencies regarding the inclusion of TXM in the drug stockpiling initiative for pandemic preparedness.
• Carefully watch the CDC monitoring system for bird flu transmissions to humans during the upcoming months.
• Explore partnership opportunities for legacy oncology assets (rigosertib and narazaciclib) for further development.

Key Dates

Recommendation

The company presents a mixed bag for a seasoned investor. While the reported net loss shows a dramatic improvement, this is largely due to the absence of a one-time charge from the prior year, not a fundamental shift in operational profitability. Cash burn continues, and the cash runway is limited to Q1 2026, suggesting a future capital raise is likely. However, the clinical pipeline, particularly the antiviral programs for COVID-19 (ratutrelvir) and influenza (TXM), shows promising preclinical and Phase 1 data, addressing significant market needs. The strategic focus on these high-potential assets and the pursuit of government stockpiling for TXM are positive. The deferral of the bird flu study is a setback, but the company is actively seeking partnerships for its legacy oncology assets. Given the early-stage nature of the promising assets, the cash position, and the inherent risks in drug development, a 'hold' recommendation is appropriate. Investors should monitor clinical trial progress, cash management, and any future capital raising activities closely.

Keywords

Antiviral, COVID-19, Influenza, Bird Flu, Ratutrelvir, Tivoxavir Marboxil, Biopharmaceutical, Clinical Stage, SEC Filing, 8-K, Drug Development, Protease Inhibitor, Endonuclease Inhibitor, Long COVID, Stockpiling, BARDA, FDA, Oncology, Rigosertib